1.Wu, J., He, J., Liu, Z., Zhu, X., Li, Z., Chen, A., & Lu, J. (2024). Cuproptosis: Mechanism, role, and advances in urological malignancies. Medicinal research reviews, 10.1002/med.22025. Advance online publication.https://doi.org/10.1002/med.22025IF: 13.3 Q1.共同通讯作者
2.Ji, J., Xu, R., Ding, K., Bao, G., Zhang, X., Huang, B., Wang, X., Martinez, A., Wang, X., Li, G., Miletic, H., Thorsen, F., Bjerkvig, R., Xiang, L., Han, B., Chen, A., Li, X., & Wang, J. (2019). Long Noncoding RNA SChLAP1 Forms a Growth-Promoting Complex with HNRNPL in Human Glioblastoma through Stabilization of ACTN4 and Activation of NF-κB Signaling. Clinical cancer research, 25(22), 6868–6881.https://doi.org/10.1158/1078-0432.CCR-19-0747IF: 11.5 Q1.共同通讯作者
3.Wang, X., Han, M., Wang, S., Sun, Y., Zhao, W., Xue, Z., Liang, X., Huang, B., Li, G., Chen, A., Li, X., & Wang, J. (2022). Targeting the splicing factor NONO inhibits GBM progression through GPX1 intron retention. Theranostics, 12(12), 5451–5469.https://doi.org/10.7150/thno.72248IF: 12.4 Q1.共同通讯作者
4.Zhao, F., Yao, Z., Li, Y., Zhao, W., Sun, Y., Yang, X., Zhao, Z., Huang, B., Wang, J., Li, X., & Chen, A. (2024). Targeting the molecular chaperone CCT2 inhibits GBM progression by influencing KRAS stability. Cancer letters, 216844. Advance online publication.https://doi.org/10.1016/j.canlet.2024.216844IF: 9.7 Q1.共同通讯作者
5.Li, Y., Liu, X., Zhao, F., Zhao, Z., Li, X., Wang, J., Huang, B., & Chen, A. (2024). Comprehensive analysis of PSMD family members and validation of PSMD9 as a potential therapeutic target in human glioblastoma. CNS neuroscience & therapeutics, 30(2), e14366.https://doi.org/10.1111/cns.14366IF: 5.5 Q1.共同通讯作者
6.Zhang, X., Yao, Z., Xue, Z., Wang, S., Liu, X., Hu, Y., Zhang, Y., Wang, J., Li, X., & Chen, A. (2022). Resibufogenin Targets the ATP1A1 Signaling Cascade to Induce G2/M Phase Arrest and Inhibit Invasion in Glioma. Frontiers in pharmacology, 13, 855626.https://doi.org/10.3389/fphar.2022.855626IF: 5.6 Q1.共同通讯作者
7.Chen, A., Zhao, W., Li, X., Sun, G., Ma, Z., Peng, L., Shi, Z., Li, X., & Yan, J. (2022). Comprehensive Oncogenic Features of Coronavirus Receptors in Glioblastoma Multiforme. Frontiers in immunology, 13, 840785.https://doi.org/10.3389/fimmu.2022.840785IF: 7.3 Q1.共同通讯作者
8.Chen, A., & An, Z. (2023). Editorial: The advances in proteomics and targeted therapy of malignant brain tumours. Frontiers in oncology, 13, 1195847.https://doi.org/10.3389/fonc.2023.1195847Q2.通讯作者和第一作者
9.陈安静,张训.靶向小类泛素化修饰的胶质瘤治疗新策略[J].山东大学学报(医学版),2020, 58(8): 88-94. Anjing CHEN#*, Xun ZHANG. The new strategies of targeting SUMOylation in the treatment of glioma[J].Journal of Shandong University (Health Sciences), 2020, 58(8): 88-94.通讯作者和第一作者